NCT01120223

Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Safety and Efficacy of Calcipotriol Plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: LEO Pharma · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 gel in adolescent subjects (aged 12 to 17) with scalp psoriasis. LEO 80185 gel has marketing approval in many countries under the brand names Xamiol® gel and Taclonex Scalp® Topical Suspension for the treatment of scalp psoriasis in adults. No studies have been performed in subjects younger than 18 years

Conditions

• Scalp Psoriasis

Interventions

Type	Name	Description
DRUG	LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)	Once daily application

Timeline

• Start date: 2010-05-01
• Primary completion: 2012-08-01
• Completion: 2012-10-01
• First posted: 2010-05-10
• Last updated: 2025-03-11
• Results posted: 2014-12-01

Locations

17 sites across 3 countries: Canada, France, United Kingdom